Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Files An 8-K …

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, an open-label extension trial which allows patients who have completed  the STAR 1 clinical trial to receive treatment with ZYN002 CBD gel for up to 52 weeks.

“STAR 2 is designed to provide additional tolerability and safety information for ZYN002 CBD gel for up to 52 weeks, which we believe will establish that ZYN002 CBD gel is well-tolerated over long-term use,” said Armando Anido, CEO of Zynerba. “Enrollment in STAR 1 is continuing and we plan to report top line results in the first half of 2017.”

STAR 2 is a multi-center, open-label Phase 2 clinical trial in which epilepsy patients with refractory focal seizures who complete the STAR 1 study will

... read more at: http://marketexclusive.com/zynerba-pharmaceuticals-inc-nasdaqzyne-files-8-k-announces-initiation-star-2-open-label-extension-clinical-trial-zyn002-cbd-gel-adult-refractory-epilepsy-patients/35787/

by